CTOs on the Move

Harken Health

www.harkenhealth.com

 
Harken Health is a new kind of health care company that unites relationship-based primary care with a range of competitively priced insurance plan options. Our care approach is rooted in the values of a simpler time when the doctor-patient relationship mattered. Harken Health Care Teams are empowered with the time to listen and build authentic, compassionate, trusting relationships with members. Our model enables us to remove many of the barriers that often get in the way of delivering exceptional care. Strong relationships and a home base for primary care have been shown to improve patient satisfaction and lower overall medical ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Peter Vladimirov
Chief Technology Officer Profile

Similar Companies

Lillibridge Healthcare Services

Lillibridge Healthcare Services is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

MDoffice

MDoffice is a Edison, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Somanetics Corporation

Somanetics Corporation is a Troy, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NutraClick

NutraClick is a technology-driven health and wellness products company committed to enriching consumers’ lives. The company’s award-winning brands include Force Factor, Peak Life, Stages of Beauty, Bona Clara, Femme Factor, and ProbioSlim. Headquartered in Boston, Mass., NutraClick leverages the power of online marketing to drive multi-channel demand. NutraClick products are available online and in more than 30,000 retail locations globally, including GNC, CVS and Walmart. For additional information, please visit www.nutraclick.com and follow us on Twitter.

StemCells

StemCells, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery primarily in the United States. Its lead therapeutic product candidate, HuCNS-SC cells (purified human neural stem cells), is in development as a potential treatment for a range of central nervous system disorders. The company has conducted a Phase I clinical trial in Pelizaeus-Merzbacher disease, a fatal myelination disorder in children. It is also conducting a Phase I/II clinical trial in chronic spinal cord injury; and has initiated a Phase I/II clinical trial in dry age-related macular degeneration, as well as is pursuing preclinical studies in Alzheimer’s disease. In addition, the company markets a rage of proprietary cell culture products, research grade human cells, and antibody reagents under the SC Proven brand. The proprietary cell culture products include iSTEM, GS1-R, GS2-M, RHB-A, RHB-Basal, NDiff227, NDiff N2, and NDiff N27 supplements, as well as HEScGRO and ESGRO Complete; and antibody reagents comprise STEM24, STEM101, STEM121, and STEM123, which can be used for cell detection, isolation, and characterization. Further, StemCells is involved in developing and commercializing applications of its technologies to enable stem cell-based research. The company sells its tools and technologies products to researchers at academic institutions, pharmaceutical and biotechnology companies, and government laboratories. StemCells, Inc. was founded in 1988 and is headquartered in Newark, California.